Tagged with BIO

Genzyme Genzyme Turkey’s general manager discusses diagnosis and treatment access issues for rare diseases, the need for prioritization of patient welfare in all aspects of health policy, and the importance of the Turkish market and its potential to Genzyme globally. For rare diseases, do Turkish patients have adequate access to the…

biotech Landsteiner is betting on biotech and genomics. The head of new developments and the head of genomic research share their views on the future of the company as well as the importance of embedding new technology in new product developments to better adapt to the changing needs of the Mexican…

Amgen One of the new generation of pharmaceutical general managers in Romania discusses the complexities of introducing innovative therapies on the market and explains how the country has become the ‘to-go-to’ destination for relocating pharma companies’ support services. Amgen has been present in Romania as far back as 2004. Can you…

biotech As in human health, innovation is key in the animal health industry. The CEO and second generation at the head of Tornel presents the company’s most important milestones since its establishment back in 1976, how the Group started export operations to the Middle East as well as how it is collaborating…

basic research Considered one of the leading medical authorities in the country, David Kershenobich provides an overview about the new challenges faced by the Mexican healthcare system with the transition from infectious to chronic-degenerative diseases, how the institute is implementing new patient centered care models to encourage prevention of risk factors and…

biotech SillaJen’s CEO shares his passion for his companies oncolytic vaccinia virus, and its potential to revolutionize the treatment of solid tumor cancers, even arguing that it may eventually constitute ‘a cure for cancer’.   Could you please introduce yourself Dr. Moon, and tell us how you became involved with SillaJen? …

biosimilars Christopher Ko was appointed as the Chief Executive Officer of Samsung Bioepis in 2012, then newly founded Korean pharmaceutical company with expertise in biosimilars. In this interview, he discusses the opportunities in Biosimilar markets as well as the potential impact the Samsung brand will bring to the pharmaceutical industry. As…

biosimilars Brothers Juan José and Andrés Aguirre Salazar of Grupo Bruluart talk about the company’s most important milestones and how they are institutionalizing the family business to prepare the firm for new market opportunities. Could you walk us through the most important milestones of the company and provide our readers with…

investemnt The stability of Peru’s economy in recent years has provided amply opportunity for multinational pharmaceutical companies to invest in the country. Augusto Rey de la Cuba, executive director of ALAFARPE (Asociación Nacional de Laboratorios Faramcéuticos de Perú), discusses intellectual property issues and investing in research in the country. Can you…

biotech After a lengthy career at Novartis, Angie Kim recently started working at BMS Korea to develop the affiliate. She discusses diversifying the company’s portfolio and their footprint in Korea as a clinical trial host. What inspired your transition? There were a few reasons, the primary reason being family and my…

biotech On February second, the Korean Ministry of Health and Welfare announced the start of a second round of financing to the biopharmaceutical industry, as part of the Global Pharmaceutical Industry Development Fund (GPIDF). A total of USD 123 million will be invested in Korean pharmaceutical and biotech companies for the…

biotech The executive managing director of a leading American healthcare provider offering an innovative range of products on the local Algerian market treating asthma, diabetes, hepatitis and cholesterol speaks about the company’s experience and the country’s ambition to become a biotech leader For the pharmaceutical industry, the African continent – especially…